[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100564959":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":22,"responsibleParty":86,"collaborators":88,"id":92,"slug":93,"hasResults":94,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":94,"sex":99,"minAge":100,"maxAge":7,"enrollmentInfo":101,"targetDuration":7,"studyType":104,"phases":7,"briefSummary":105,"conditions":106,"keywords":112,"overallStatus":25,"whyStopped":7,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":132},{"fullName":5,"class":6},"Oxford Biodynamics Inc.","INDUSTRY",null,[9],{"name":10,"affiliation":11,"role":12},"Ryan Mathis, MD","Oxford BioDynamics","STUDY_DIRECTOR",[14,18],{"name":10,"role":15,"phone":16,"phoneExt":7,"email":17},"CONTACT","888-200-3361","ryan.mathis@myobdx.com",{"name":19,"role":15,"phone":20,"phoneExt":7,"email":21},"Joseph DeSimone, BA","803-329-7772","joseph@ccorn.net",[23,50,69],{"facility":24,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Eastern Connecticut Hematology and Oncology","RECRUITING","Norwich","Connecticut","06360","United States","US",{"type":32,"coordinates":33},"Point",[34,35],-72.07591,41.52426,{"lat":35,"lon":34},[38,42,47],{"name":39,"role":15,"phone":40,"phoneExt":7,"email":41},"Susan Johnson, MD","(860) 886-8362","sjohnson@echoct.com",{"name":43,"role":15,"phone":44,"phoneExt":45,"email":46},"Stephanie Pacheco","860-886-8362","253","SPacheco@echoct.com",{"name":48,"role":49,"phone":7,"phoneExt":7,"email":7},"Dennis Slater, MD","PRINCIPAL_INVESTIGATOR",{"facility":51,"status":25,"city":52,"state":53,"zip":54,"country":29,"countryCode":30,"cosmosGeoPoint":55,"geoPoint":59,"contacts":60},"Cancer Center of Middle Georgia","Dublin","Georgia","31021",{"type":32,"coordinates":56},[57,58],-82.90375,32.54044,{"lat":58,"lon":57},[61,65,68],{"name":62,"role":15,"phone":63,"phoneExt":7,"email":64},"Harsha Vyas, MD","(478) 272-8266","hvyas@ccmgeorgia.com",{"name":66,"role":15,"phone":63,"phoneExt":7,"email":67},"Audrey Bryan, BS","abryan@ccmgeorgia.com",{"name":62,"role":49,"phone":7,"phoneExt":7,"email":7},{"facility":70,"status":25,"city":71,"state":72,"zip":73,"country":29,"countryCode":30,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"Carolina Blood and Cancer Care Associates","Rock Hill","South Carolina","29732",{"type":32,"coordinates":75},[76,77],-81.02508,34.92487,{"lat":77,"lon":76},[80,83,85],{"name":81,"role":15,"phone":20,"phoneExt":7,"email":82},"Sashi Naidu, MD","snaidu@cbcca.net",{"name":19,"role":15,"phone":20,"phoneExt":7,"email":84},"jdesimone@cbcca.net",{"name":81,"role":49,"phone":7,"phoneExt":7,"email":7},{"type":87,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[89],{"name":90,"class":91},"Community Clinical Oncology Research Network, LLC","UNKNOWN","100564959","a-prospective-real-world-evidence-study-prowes-for-concordance-rate-of-blood-based-3d-genome-conformation-mapping-episwitch-cirt-to-identify-likelihood-of-response-and-actual-response-rates-to-pd-l-1-checkpoint-inhibitors-across-multiple-oncological-indications-100564959",false,"NCT06635954","A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.","PROWES","Inclusion Criteria:\n\n1. 18 years of age or older\n2. Stage III or IV cancer\n3. Selected by their healthcare provider to receive the Episwitch CiRT® test according to the current evidence-based schedule (per protocol) as part of their standard of practice.\n4. ECOG performance status ≤ 2\n5. Clinically eligible for ICI therapy\n6. Able to read, understand and provide written informed consent.\n7. Willing and able to comply with the study requirements\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding\n2. History of bone marrow or organ transplant\n3. Contra indication for receiving Immune Check Point inhibitor.","ALL","18 Years",{"count":102,"type":103},2000,"ESTIMATED","OBSERVATIONAL","The purpose of this research is to test whether a blood-based 3D genome conformation mapping test called the Episwitch CiRT® can help to identify likelihood of response to PD-(L)-1 checkpoint inhibitors (a class of cancer drugs) across multiple oncological indications by comparing the results to actual treatment responses for cancer patients.",[107,108,109,110,111],"Cancer","Immunotherapy","PD-1","PD-L1","Immune Checkpoint Therapy",[113,114,115,116,117,118,119,120,121,122,109,110],"immunotherapy","immune checkpoint inhibitor","ICI therapy","ICI","Immune Checkpoint Inhibitor therapy","Episwitch","Episwitch CiRT","Immune Related Adverse Event","IRAE","cancer","2025-03-12",{"date":125,"type":126},"2025-03-17","ACTUAL",{"date":128,"type":126},"2024-05-14",{"date":130,"type":103},"2027-05-14",{"name":5,"class":6},3]